TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07416526: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Factor VIII Prophylaxis in People With Hemophilia A Without Inhibitors

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 138 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$877,560

Rescue Site Savings

+$585,040

Unlock Full NCT07416526 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07416526 Rescue Dossier →